Peptides as Potential Therapeutics for Alzheimer’s Disease
AbstractIntracellular synthesis, folding, trafficking and degradation of proteins are controlled and integrated by proteostasis. The frequency of protein misfolding disorders in the human population, e.g., in Alzheimer’s disease (AD), is increasing due to the aging population. AD treatment options are limited to symptomatic interventions that at best slow-down disease progression. The key biochemical change in AD is the excessive accumulation of per-se non-toxic and soluble amyloid peptides (Aβ(1-37/44), in the intracellular and extracellular space, that alters proteostasis and triggers Aβ modification (e.g., by reactive oxygen species (ROS)) into toxic intermediate, misfolded soluble Aβ peptides, Aβ dimers and Aβ oligomers. The toxic intermediate Aβ products aggregate into progressively less toxic and less soluble protofibrils, fibrils and senile plaques. This review focuses on peptides that inhibit toxic Aβ oligomerization, Aβ aggregation into fibrils, or stabilize Aβ peptides in non-toxic oligomers, and discusses their potential for AD treatment. View Full-Text
Share & Cite This Article
Ribarič, S. Peptides as Potential Therapeutics for Alzheimer’s Disease. Molecules 2018, 23, 283.
Ribarič S. Peptides as Potential Therapeutics for Alzheimer’s Disease. Molecules. 2018; 23(2):283.Chicago/Turabian Style
Ribarič, Samo. 2018. "Peptides as Potential Therapeutics for Alzheimer’s Disease." Molecules 23, no. 2: 283.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.